The nation of Zimbabwe has rejected a significant American healthcare agreement valued at 367 million US dollars (£272m) spanning five years because of Washington's request for sensitive data.
The decision was revealed after a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesperson later explained that the US was seeking genetic material for research and commercial gain while refused to share the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further dialogue to find a agreement agreeable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Implications
This rejection comes after a comparable situation in Kenya, where a high court suspended a similar deal with the US following concerns were filed about the security of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral deals to enhance transparency and responsibility.
Based on reports, Sixteen nations in Africa have to date agreed to similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our nation would supply the basic resources for medical research without any assurance that the end products would be available to our citizens should a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of bilateral health agreements were upending structures already established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This mechanism is designed to ensure that when a country provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to continued discussions with our American counterparts on how future collaboration might be structured in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body stated it understood the official position, but suggested that negotiations need to persist considering much of the country's HIV programmes relied on external financing.
"If technical issues arise, such as those involving information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it added.
The halted deal underscores the continuing tensions between accepting vital international aid and protecting national sovereignty in an ever more data-driven world.